Targeting IGF1R Overcomes Armored and Cold Tumor Microenvironment and Boosts Immune Checkpoint Blockade in Triple‐Negative Breast Cancer
Advanced Science · 2025-10 · 12 (39)
DOI: 10.1002/advs.202501341 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 18.07.2025. Verfasst von Mengyun Wan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology, School of Basic Medical Sciences, Nanjing Medical University, Nanjing, 211166, China. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Tumor Microenvironment, Immune Checkpoint Inhibitors, Receptor, IGF Type 1. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
In the previous study, patients with tumors based on collagen deposition and immunoreactivity are classified and identified the armored & cold subtype as the most treatment‐refractory tumor type. Triple‐negative breast cancer (TNBC) is the most lethal tumor type globally, making it critical to overcome the armored and cold tumor microenvironment (TME) for effective treatment of these patients. In this study, the transcriptomic collagen activity and immune profiles of cancer patients treated with immune checkpoint blockade (ICB) are analyzed, and found that intratumoral collagen is associated with an unfavorable immunotherapeutic response and T cell exhaustion. Additionally, collagen is shown to regulate IGF1R expression at both transcriptional and post‐translational levels via SOX4 and DDR1, respectively. It is also found that IGF1R promotes tumor cell migration and invasion, as well as T cell exhaustion, with these effects mediated through collagen. Moreover, in vivo inhibition of IGF1R reversed the armored & cold TME, thereby enhancing anti‐PD‐1 therapy. In conclusion, this study identified IGF1R as a novel therapeutic target for the immuno‐collagenic subtype, and combining IGF1R inhibition with anti‐PD‐1 therapy provides a promising foundation for a novel combination immunotherapy regimen for TNBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Physiology, School of Basic Medical Sciences, Nanjing Medical University, Nanjing, 211166, China.
- The First Clinical Medicine College, Nanjing Medical University, Nanjing, Jiangsu, 211166, China.
- Department of Central Laboratory, The First People's Hospital of Jintan, Jintan Affiliated Hospital of Jiangsu University, Changzhou, Jiangsu, 213251, China.
- Departments of Gynecology, Wuxi Maternity and Child Health Care Hospital, Affiliated Women's Hospital of Jiangnan University, Wuxi, Jiangsu, 214023, China.
- Departments of Gynecology, Wuxi Maternal and Child Health Care Hospital, Wuxi Medical Center, Nanjing Medical University, Wuxi, Jiangsu, 214023, China.
- Department of Geriatrics, The Fourth Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, 211800, China.
ORCID-Profile: Yan Zhang
Zitieren
APA
Wan, M., Mei, J., Cai, Y., Zhou, J., Xue, N., Jiang, Y., Zhang, Y., Huang, J., & Zhu, Y. (2025). Targeting IGF1R Overcomes Armored and Cold Tumor Microenvironment and Boosts Immune Checkpoint Blockade in Triple‐Negative Breast Cancer. Advanced Science, 12(39). https://doi.org/10.1002/advs.202501341
Vancouver
Wan M, Mei J, Cai Y, Zhou J, Xue N, Jiang Y, et al. Targeting IGF1R Overcomes Armored and Cold Tumor Microenvironment and Boosts Immune Checkpoint Blockade in Triple‐Negative Breast Cancer. Advanced Science. 2025;12(39). doi:10.1002/advs.202501341
BibTeX
@article{Wan2025,
author = {Wan, Mengyun and Mei, Jie and Cai, Yun and Zhou, Ji and Xue, Ningyi and Jiang, Ying and Zhang, Yan and Huang, Jingjing and Zhu, Yichao},
title = {Targeting IGF1R Overcomes Armored and Cold Tumor Microenvironment and Boosts Immune Checkpoint Blockade in Triple‐Negative Breast Cancer},
journal = {Advanced Science},
year = {2025},
volume = {12},
number = {39},
doi = {10.1002/advs.202501341}
}
EUVIMED